Comparison of Immunogenic Potentials of Bovine Thrombin Preparations

Clinical and Applied Thrombosis/Hemostasis - Tập 15 Số 1 - Trang 41-49 - 2009
He Zhu1, Debra Hoppensteadt1, Cafer Adıgüzel1, Rodger L. Bick1, Jawed Fareed1
1Department of Pathology, Loyola University Medical Center, Maywood, Illinois

Tóm tắt

Using a membrane filtration step, bovine crude thrombin was purified into thrombin 4A and 4B preparations. The purpose of this study was to determine whether the improved purity of a bovine thrombin preparation can reduce its overall immunogenic potential and lower the risk of development of factor V antibodies. Bovine crude thrombin and its purified versions, thrombin 4A and 4B, were administered to individual groups of rabbits on days 0, 21, 42, 91, 123, and 151 using standard immunologic methods. Blood was drawn from each rabbit on days 30, 50, 105, 137, and 165, and the pooled antisera from individual groups were purified to obtain the Ig Gs using protein G affinity columns. Using Western blotting, the specificity of each immunoglobulin G collected at the first time point (day 30) and last time point (day 165) was determined. The results of Western blotting using the Ig Gs collected on days 30 and 165 were consistent; both demonstrating that thrombin 4B has the least immunogenic potential among the 3 thrombin preparations tested. Compared with the immunoglobulin Gs collected on day 30, the Ig Gs from day 165 did not show obvious difference regarding their ability to detect antigens in bovine thrombin samples. Neither showed cross-reactivity with human coagulation factors nor the recognition of bovine factor Va antigens. These results suggest that despite the presence of a trace amount of bovine factor Va antigen in bovine thrombin preparations, these contaminants failed to elicit the generation of antibodies against factor Va light chain in rabbit

Từ khóa


Tài liệu tham khảo

10.1023/A:1026455631876

10.1055/s-2006-939559

10.1002/jbm.10025

10.1002/ajh.2830450206

10.1093/ajcp/97.1.84

10.1016/S0022-5223(19)33804-8

10.1055/s-0038-1655966

10.1182/blood.V76.10.2011.2011

10.1097/00000658-200101000-00014

10.1046/j.1537-2995.2002.00011.x

10.1016/j.jamcollsurg.2007.03.020

10.1016/j.jvs.2008.01.034

Dorion RP, 1998, Arch Pathol Lab Med, 122, 887

10.1111/j.1365-2141.1993.tb03343.x

10.1016/S0950-3536(98)80050-4

10.1016/0091-6749(91)90156-I

10.1016/S0021-9258(17)37898-5

10.1016/S0021-9258(17)34206-0

10.1016/S0021-9258(20)65178-X

10.1016/S0021-9258(17)43427-2

10.7326/0003-4819-111-8-631

10.1182/blood.V72.4.1375.1375

10.1172/JCI106375

10.1097/00000441-197305000-00008

10.1002/ajh.2830040212

10.1177/1076029607308866

Zhu H., 2008, Clin Appl Thromb Hemost

10.1016/S0021-9258(19)44948-X

Thông tin
Thông tin xuất bản

Clinical and Applied Thrombosis/Hemostasis

Tập 15 Số 1

41-49

Thông tin tác giả